Telemedicine and Telehealth Fraud Defense

You saw patients over a telehealth platform, built or ran the platform, or connected doctors to the companies that needed orders, and now the government is calling it fraud. Telemedicine fraud is the connective tissue of modern healthcare fraud enforcement. The same telehealth model sits underneath the biggest genetic testing, DME, and prescription schemes the Department of Justice has charged, and prosecutors have moved from indicting the labs and suppliers to indicting the doctors who signed and the platforms that arranged it. If you have received a target letter, a subpoena, or a visit from agents, you are already inside the investigation.

This page explains how telemedicine cases are built and defended, in plain terms, for the physician, platform operator, or marketer who is worried about exposure.

Why telehealth turned into an enforcement priority

Telehealth is legal and, since the pandemic, everywhere. The prosecutions are not about practicing medicine online. They are about two things: whether a real physician-patient relationship existed, and whether money was paid to generate orders.

The pattern the government charges is consistent. A platform or marketing company routes Medicare beneficiaries to physicians. The physician signs orders for braces, genetic tests, pain creams, or prescription drugs, often after a brief call or no meaningful encounter at all, and is paid per consult or per order. A lab, DME supplier, or pharmacy then bills Medicare. Prosecutors describe the telehealth visit as a rubber stamp that manufactured the paperwork to justify the billing, and they describe the per-order payments as kickbacks.

The COVID-era expansion of telehealth created an enormous paper trail. That trail is now the evidence.

How telemedicine investigations start

These cases begin with data and platform records. Analytics flag physicians who signed an unusually high volume of orders, or platforms whose doctors did. The government then pulls the consult logs, the payment records, the marketing contracts, and the downstream billing. The signing physician is easy to identify because the order carries a name. HHS-OIG and the FBI build the financial picture. When agents reach you, the question is intent: did you know the encounters were not real medicine and the payments were for orders.

What the government has to prove

Telemedicine cases are charged under 18 U.S.C. 1347, the Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), conspiracy under 18 U.S.C. 1349, and wire fraud under 18 U.S.C. 1343. When laboratories are in the chain, EKRA, 18 U.S.C. 220, applies too. The government must prove you acted knowingly and willfully. A physician who believed the platform delivered legitimate patients, reviewed records, and made real clinical judgments is not a criminal because a lab downstream committed fraud. The rubber-stamp label is an argument, not a fact, and it is the government's burden.

The exposure runs wide

Section 1347 carries up to ten years per count, twenty if patient harm is alleged, and each kickback count adds up to ten years. The government adds forfeiture, sometimes money laundering, and civil liability under the False Claims Act, 31 U.S.C. 3729. For physicians, an indictment threatens the medical license, DEA registration, and the ability to bill federal programs. Because the signing doctor's name is on every order, physicians are often exposed to large aggregate loss figures even when their per-order payment was small.

How telemedicine cases are defended

Rebuild the encounter. The heart of the defense is showing the telehealth visits were real medicine: intake records, patient histories, clinical notes, and standard-of-care judgments. The government wants to try these in bulk. Each encounter is its own fact.

Use the pandemic waivers correctly. Federal telehealth rules were relaxed during the public health emergency, and what was permissible shifted over time. The rules in force on the date of the conduct matter, and the government does not always apply them accurately.

Attack the kickback characterization. Fair-market-value compensation for legitimate physician services is not a kickback. We test the pay structure against the Anti-Kickback Statute and its safe harbors, and separate payment for work from payment for orders.

Show what the client could see. Platform operators and physicians usually saw one slice of the operation. We build the record of what your client actually knew and controlled, which limits both liability and loss. The downstream biller, whether a genetic testing lab, a DME supplier, or a pharmacy, sat in a different position than the signing doctor.

Why the timing decides the case

Telemedicine investigations develop over many months, and there is almost always a pre-indictment window. That window is where a physician can be moved from target to witness, where a platform can present its compliance structure, and where counsel can argue a client out of the case before a grand jury ever sees it. After indictment, that leverage is gone. In this area, the providers who wait for charges before hiring counsel give up the phase where the case is most winnable.